Lowery MA, et al. - In patients with previously treated BRCA1/2- or PALB2-mutant pancreatic adenocarcinoma (PDAC), the response rate of veliparib was evaluated. In this single arm, non-randomised, multicentre phase II trial, veliparib was well tolerated, however, no confirmed response was noted although 25% patients remained on study with stable disease (SD) for ≥ 4 months.